310 related articles for article (PubMed ID: 18485547)
1. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
[TBL] [Abstract][Full Text] [Related]
3. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
6. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response.
Rath A; Choudhury S; Batra D; Kapre SV; Rupprecht CE; Gupta SK
Virus Res; 2005 Nov; 113(2):143-52. PubMed ID: 15978691
[TBL] [Abstract][Full Text] [Related]
8. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.
Bissa M; Pacchioni SM; Zanotto C; De Giuli Morghen C; Illiano E; Granucci F; Zanoni I; Broggi A; Radaelli A
Virus Res; 2013 Dec; 178(2):374-82. PubMed ID: 24050999
[TBL] [Abstract][Full Text] [Related]
9. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
Hooper JW; Thompson E; Wilhelmsen C; Zimmerman M; Ichou MA; Steffen SE; Schmaljohn CS; Schmaljohn AL; Jahrling PB
J Virol; 2004 May; 78(9):4433-43. PubMed ID: 15078924
[TBL] [Abstract][Full Text] [Related]
10. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
Shinoda K; Wyatt LS; Irvine KR; Moss B
Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
[TBL] [Abstract][Full Text] [Related]
11. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
16. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.
Golden JW; Hooper JW
Clin Vaccine Immunol; 2010 Nov; 17(11):1656-65. PubMed ID: 20844086
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy.
Otero M; Calarota SA; Dai A; De Groot AS; Boyer JD; Weiner DB
Vaccine; 2006 May; 24(21):4461-70. PubMed ID: 16137803
[TBL] [Abstract][Full Text] [Related]
19. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.
Aldaz-Carroll L; Whitbeck JC; Ponce de Leon M; Lou H; Pannell LK; Lebowitz J; Fogg C; White CL; Moss B; Cohen GH; Eisenberg RJ
Virology; 2005 Oct; 341(1):59-71. PubMed ID: 16083934
[TBL] [Abstract][Full Text] [Related]
20. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
